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ABSTRACT 
In a prospective study we compared two different dosage regimens of IV chioramphenicol succinate
(100 mg/kg/day and 75 mg/kg/day) in children with culture proven typhoid. Trough and peak blood
samples, obtained at 48 hrs, were analysed for free chioramphenicol by high pressure liquid
chromatography (HPLC). Although the mean trough (8.8±1.7 versus 5.4±2.6 mcg/ml) and peak
(19.9±12.2 versus 15.4±6.1 mcg/ml) chloramphenicol concentrations were comparable in both groups,
a ‘significantly wider range was found in the group receiving 100 mg/kg/day. Potentially toxic levels
(>30 mcg/ml) developed in two patients with liver dysfunction. Chloramphenicol in a dosage of 75
mg/kg/day Is adequate and safe for the treatment of paediatric typhoid (JPMA 91: 26, 1991).
INTRODUCTION 
Chloramphenicol is considered as the treatment of choice in typhoid fever1. The oral preparation,
Chioramphenicol palmitate is used in the treatment of typhoid except when vomiting ileus or toxicity
preclude oral therapy. Intravenous succinate ester of chloramphenicol are used in such circumstances.
Free chioramphenicol. after the succinate or palmitate group has been cleaved, is the microbiologically
active form which isexcretçd following glucuronidation in the liver. The various known path- ways2-5
of human metabolism of chloramphenicol suecinate (CS) are shown in Figure 1.
The. metabolism of chioramphenicolpalmitate in the liver is similar, except for the initial hydrolysis of
the pahnitate ester in the gastrointestinal tract lumen6. Some studies have demonstrated wide variability
in the pharmacokinetics of CS2,3. This is chiefly related to variation in the rate o1 hydrolysis of the
succinate ester in the iiver and urinary losses of CS2,7. There is very little data on chioramphenicol
pharmacokinetics in typhoidal salmonellosis. Little still, is known about appropriate dosage in children
with typhoid fever and dosage schedules ranging from 50 - 100 mg/kg! day have been recommended8.
As free chloramphenicol is principally conjugated in the liver, therefore impaired chioramphenicol
clearance and potentially toxic serum levels may develop, in patients with liver dysfunction9,10. The
association of hepatic dysfunctionwith typhoid has also been demonstrated in adults11,12 and children13
in a number of studies. The use of chlorainphenicol therefore, in children with typhoid and hepatic
dysfunction may also be associated with potential toxicity. We conducted a prospective study to
compare two different dosage schedules of CS in paediatric typhoidal salmonellosis, and to assess the
effect of concomitant hepatic dysfunction on serum concentrations of chloramphenicol.
PATIENTS AND METHODS 
The study was conducted over an 18 months period (May 1987 - September 1988) at the Aga Khan
University Hospital (AKUH), Karachi. Patient selection: All children (age 6 months - 14 years)
presenting to the Department of Paediatrics with suspected typhoid were studied. Patients were
prospectively randomized for inclusion in the study using sealed envelopes containing the
randomization dose. Children with neutropenia (neutrophils <1000/mm3) and those who had received
chloramphenicol therapy in the preceding 7 days, were excluded from the study. Informed consent was
obtained from the parents/guardians of the children prior to inclusion in the study. The children were
nursed for the duration of the study on the paediatric ward and examined twice daily by a medical
officer. Chloramphenicol dosage schedule & administraUon: Patients were randomized to receive
intravenous CS either 100 mg/kg! day (Group A) or 75 mg/kg/day (Group B) intravenously in a six
hourly dosage for 48 hours. The drug was administered after dilution in normal saline as an infusion
over 30 minutes. A daily record of clinical status, including temperature, mental status, hydration,
jaundice, abdominal discomfort, visceromegaly, diarrhoea and vomiting was maintained. The patients
were discharged home on oral chioramphenicol palmitate in the same dosage after remaining afebrile
for 24 hrs (axillary temperature 37°C).
Laboratory investigations: A blood culture was obtained in all cases with suspected typhoid fever. Two
blood culture bottles (containing brain heart infusion and thioglycollate broth) were inoculated with 2-3
ml of venous blood and incubated for 7 days at 37°C. A bone marrow culture was also obtained and
inoculated similarly, if there was a history of prolonged illness ( >15 days) or antibiotic administration
for >72 hours prior to presentation. Each culture bottle was examined daily and subcultured onto blood
agar and MacConkey\'s media after 24, 48 and 72 hours and on the 5th and 7th day of incubation, non-
lactose fermenting colonies from MacConkey’s medium were tested for salmonella by slide
agglutination with specific antisera.A stool microscopy and culture were obtained if there was
concomitant diarrhoea at presentation and stool specimens were similarly cultured on MacConkey agar.
Biochemical tests for identification were performed, using API 20E strips (Analytical Profile Index API
System, S.A. Lambalmeles Grottes-38390, Montalieu, Vercien, France). Baseline investigations
including complete blood count (CBC), differential count, reticulocyte count, serum bilirubin, SGPT
(Alanine transaminase), Alkaline phosphatase and bicarbonate, were obtained at admission prior to
institution of therapy.These investigations were repeated after 48 hours of therapy. CBC was analyzed
on a coulter counter (Coulter Inc, USA) whereas the bicarbonate and liver function profile were
assessed on an autoanalyzer (Beckmann Inc., Astra, Ca).
Chloramphenicol sampling and assay: Blood samples (3 ml) were obtained by venepuncture 48 hours
after initiation of therapy, before and one .hour after cessation of chloramphenicol infusion. Plasma was
frozen at -80°C until analysis. Analysis was done on 50 microlitre sample of plasma by high pressure
liquid chromatography (HPLC) using the method of Nielsson-Ehle et al14 with some modifications.
Novapak, microbondapak C18 column, 25cm x 2.1 mm id., (Waters Associates, USA) was used.
Mobile phase was acetic acid, water and methanol in ratios of 1:62:37. Flow rate of mobile phase was
1.0 ml per minute. The FIPLC system (Waters Associates, USA) consisted of a pump M- 6000 A; a
variable LC spectrophotometer 440 with absorbance set at 280 nm; WISP 710 B injector, Data Module
730 and a System Controller 720. All solvents used were of ultra high purification HPLC grade. Free
chloramphenicol for standards, was obtained from Parke Davis (Pakistan) Ltd. Standard curve of
chloramphenicol was constructed using 5, 10,20,30 and 50 mcg free chioramphenicol per ml. A four
point standard curve, prepared in water, included concentrations of 50 to 6.25 mcg/ml. Peaks were
detected under isocratic conditions. Linear regression analysis of Peak heights and chioramphenicol
concentrations gave a correlation coefficient of 0.99. Concentration of free chloramphenicol in plasma
was calculated from the standard curve and reported as mcg free chioramphenicol /ml (Figure 2).
Follow up: All patients were followed up for 12 weeks after discharge to assess clinical status.
Statistical analysis: Data was analysed using chi square analysis with Yates correction and t test.
RESULTS 
Twenty five children enrolled in the study had culture proven typhoid.
Table lists the clinical details for the two groups of patients studied. There was no significant difference
between the two groups for age, weight, severity of illness or baseline liver function. Although
hepatomegaly was seen in 15125 (60%) patients at admission, significant hepatic dysfunction as
evidenced by hepatomegaly and two folds elevation of SGPT was found in 4/15(27%) and 6/10 (60%)
patients in groups A and B respectively, at initiation of therapy. There was a wide range of trough
concentrations in group A which had received 100 mg/kg/ day. Two children developed trough levels of
chioramphenicolin excess of 30 mcg/ml. This led to a large standard deviation and so the difference in
the mean trough concentrations of the two groups was not statistically significant (8.8 ± 7.7 versus 5.4
± 2.6 mcg/ml, mean ± SD, x2= 0.2, P = NS). Similarly, there was a wider range of peak serum
concentrations in group A. Three children (20%) on 100 mg/kg/ day dosage, developed peak levels of
chioramphenicol in excess of 30 mcg/ml (Figure 3).
However, the mean peak serum concentrations for both dosage groups are comparable (19.9 ±
12.2versus 15.4 ± 6.1 mcg/dl, mean ± SD, X2 = 0.23, P=NS). Most of the high levels of
chioramphenicol were found in children with significant hepatic dysfunction. Four of the five children
with chioramphenicol levels greater than 30 mcg/ml had SGPT (Alanine transaminase) values >100
lUll. A significant correlation was also found between chioramphenicol trough levels at 48 hours and
corresponding serum SGPT (Alanine transaminase) values (Y = -2.5 + 0.19; r =0.68, P< 0.001) (Figure
4).
There was no significant difference between the two groups for anyof the haematological indices at 48
hours and no child developed neutropenia or anaemia. The mean reticulocyte count for group A was 1.4
± 0.6% versus 1.1 ± 0.9 % for group B (P = NS). The SGPT (Alanine transaminase) values at 48 hours
were also comparable (57 + 24 versus 54 +  24 IU/I, P=NS). The mean serum alkaline phosphatase
value was slightly higher for group. A  children at 48 hours in comparison with group B (218 + 128
versus 131 + 47 IU/1, P<0.05).  Twenty children (80%) were infected with salmonella typhi and S
paratyphi strains which were  susceptible to chloramphenicol. When these children were treated with
the two treatment  regimens, there was no difference between the two groups for time to defervescence
(4.4+2.1  versus 4.4 + 1.8 days, mean + SD, P=NS). No child relapsed after completion of the course
of  therapy. The five children infected with chloramphenicol-resistant strains of salmonella  typhi were
changed to appropriate antibiotic when the sensitivity results were available,  and all recovered
uneventfully.
DISCUSSION 
Our study aimed to study the serum levels and response to two different dosage regimens of
chloramphenicol in children with typhoid, We chose is study the intravenous preparation of
chloramphenicol but the post-hydrolytic metabolism and pharmacokinetics of the oral form i.e.
chioramphenicol palmitate is similar15 and the results would be equally applicable. The minimal
inhibitory concentration of chloramphenicol against most susceptible organisms is 0.5 - 2.0 mcg/dl16
and the usual serum levels required to achieve satisfacto7 antibacterial activity range from 5 - 20
mcg/ml3,15. . The dose related bone marrow suppression generally appears when chlorampbenicol
concentration exceed 25 mcg/ml17 and it is therefore imperative that every effort should be made to
ensure that the levels remain in the therapeutic range to avoid the risk of toxicity. With wide individual
variation in the metabolism of chloramphenicol in the paediatric age group 18,19 this may necessitate
measurement of serum levels. Studies in adults have also shown the association of chloramphenicol
toxicity with derangement of liver function20,21. Most such studies have found decreased clearance,
increased half-life and higher serum levels of chloramphenicol in association with liver disease.
Azzolini et al22 found a significant correlation between serum albumin and bilirubin values with
cbloramphenicol levels, whereas Slaughter et al7 could not find any association between liver function
tests and chloramphenicol dosage. Of the various liver disorders studied by Narang et al20 hepatitis was
associated with the highest serum chloramphenicol levels, suggesting a specific relationship with
hepatocellular derangement. The presence of significant impairment of hepatic function in some
patients with typhoid is well documented and may have a wide spectrum. The bepatic dysfunction may
be severe enough to manifest as clinical jaundice23 but is frequently subclinical, discernible on
laboratory testing only24. The exact patbogenesis of liver involvement in typhoid remains unclear. The
organisms proliferate in the reticuloendothelial system but this should not lead to hepatocellular
dysfunction. Other factors such as endotoxaemia, may also have a contributory role in the alteration of
liver function in typhoid. In our study, some children with typhoid and concomitant hepatic
dysfunction, developed potentially toxic serum concentrations of chloramphenicol after intravenous
CS. Our findings of a positive correlation between SGPT (Alanine transaminase) and trough
chloramphenicol levels at 48 hours also tends to support this observation. The clinical significance of
toxic chioramphenicol levels in our study population is unclear. None of the patients exhibited any
signs of clinical and baematological toxicity and all recovered uneventfully. Acidosis, due to probable
interference with mitochondrial electron transport has been described as an early manifestation of
chioramphenicol toxicity25. It is interesting to note that the lowest serum bicarbonate value in our study
(11 mmol/l) was seen in the infant who had significant hepatic derangement and also developed a peak
chioramphenicol concentration of 53 mcg/ml. Ideally chloramphenicol levels should be measured in all
children but this is clearly an expensive and impractical proposition for most of the developing
countries where typhoid is endemic. A safer alternative would be judicious use of chloramphenicol in
the right dosage. Our data shows that therapeutic concentrations are obtained with a dose of 75
mg/kg/day. Potentially toxic, serum concentrations of chioramphenicol are likely to occur in children
on 100 mg/kg/ day of the drug in the presence of liver dysfunction due to typhoid. Therapeutic serum
concentrations are obtained with a dose of 75 mg/kg/day with comparable clinical efficacy to the higher
dose. No instance of toxic serum concentration was found in this group of patients. We suggest that
75mg/kg/day chloramphenicol should be used as standard dose for children with typhoid. If the child
has evidence of significant hepatocellular involvement, serum concentrations should be monitored, the
dose should be further reduced or an alternative drug employed for therapy.
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